Abstract
After years of pre-clinical and clinical testing monoclonal antibodies (mAbs) finally offer new therapeutic choices for patients with haematological and solid malignancies both as unconjugated antibody and as vectors to target radionuclides in radioimmunotherapy (RIT). In recent years some of the most exciting clinical data have come from the use of RIT in the treatment of lymphoma and haematological malignancies and it would now appear highly likely that RIT will play a major role in the treatment strategies for these diseases. For the solid tumours there has also been considerable progress with RIT and mAbs have become a component of treatment protocols for breast cancer. This review highlights the important recent clinical progress that has been made with clinical RIT and provides some new insights into the important mechanisms of action of RIT in haematological malignancies.
Keywords: Target radiotherapy, monoclonal antibodies (mAbs), Radioimmunotherpy (RIT), Haematological malignancies, ADCC, Antibodies, Tumour nodules, HAMA response, Immunosuppression, Cyclosporin, Deoxysperualin, The Radioisotope, Radioimmunoglobulin, Normal tissue toxicity, Dosimetry, MIRD, Non myeloablative therapy in lymphoma, CD20 antibodies, Phase II pivotal, Complete response, Maximum Tolerated Dose, Immunoglobulin idiotype, IDEC Y2B8, Solid tumours
Current Pharmaceutical Design
Title: Radioimmunotherapy of Cancer Using Monoclonal Antibodies to Target Radiotherapy
Volume: 6 Issue: 14
Author(s): Timothy M. Illidge and Susannah Brock
Affiliation:
Keywords: Target radiotherapy, monoclonal antibodies (mAbs), Radioimmunotherpy (RIT), Haematological malignancies, ADCC, Antibodies, Tumour nodules, HAMA response, Immunosuppression, Cyclosporin, Deoxysperualin, The Radioisotope, Radioimmunoglobulin, Normal tissue toxicity, Dosimetry, MIRD, Non myeloablative therapy in lymphoma, CD20 antibodies, Phase II pivotal, Complete response, Maximum Tolerated Dose, Immunoglobulin idiotype, IDEC Y2B8, Solid tumours
Abstract: After years of pre-clinical and clinical testing monoclonal antibodies (mAbs) finally offer new therapeutic choices for patients with haematological and solid malignancies both as unconjugated antibody and as vectors to target radionuclides in radioimmunotherapy (RIT). In recent years some of the most exciting clinical data have come from the use of RIT in the treatment of lymphoma and haematological malignancies and it would now appear highly likely that RIT will play a major role in the treatment strategies for these diseases. For the solid tumours there has also been considerable progress with RIT and mAbs have become a component of treatment protocols for breast cancer. This review highlights the important recent clinical progress that has been made with clinical RIT and provides some new insights into the important mechanisms of action of RIT in haematological malignancies.
Export Options
About this article
Cite this article as:
Illidge M. Timothy and Brock Susannah, Radioimmunotherapy of Cancer Using Monoclonal Antibodies to Target Radiotherapy, Current Pharmaceutical Design 2000; 6 (14) . https://dx.doi.org/10.2174/1381612003399257
DOI https://dx.doi.org/10.2174/1381612003399257 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Design and Synthesis of 4-substituted Quinazolines as Potent EGFR Inhibitors with Anti-breast Cancer Activity
Anti-Cancer Agents in Medicinal Chemistry Molecular Docking: Challenges, Advances and its Use in Drug Discovery Perspective
Current Drug Targets Carvacrol as a Potential Neuroprotective Agent for Neurological Diseases: A Systematic Review Article
CNS & Neurological Disorders - Drug Targets Biopharmaceutics and Therapeutic Potential of Engineered Nanomaterials
Current Drug Metabolism In Vitro Antitumoral Activity of Palladium(II) and Platinum(II) Complexes with O,O'-Dialkyl Esters of Ethylene-bis(S)-Leucine
Letters in Drug Design & Discovery Natural Antioxidants: Therapeutic Prospects for Cancer and Neurological Diseases
Mini-Reviews in Medicinal Chemistry Homologation: A Versatile Molecular Modification Strategy to Drug Discovery
Current Topics in Medicinal Chemistry <i>In Vitro</i> Anti-proliferative Properties of Flavonoids Isolated from <i>Artocarpus Heterophyllus</i> on Cancer Cell Lines
The Natural Products Journal Insights into the Role of Fc Gamma Receptors (FcγRs) Genetic Variations in Monoclonal Antibody-Based Anti-Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Targeted Enzyme Prodrug Therapies
Mini-Reviews in Medicinal Chemistry Cardiotoxicity of Molecularly Targeted Agents
Current Cardiology Reviews Peptides for In Vivo Target-Specific Cancer Imaging
Mini-Reviews in Medicinal Chemistry Short-Term Intra-Nasal Erythropoietin Administration with Low Sialic Acid Content is without Toxicity or Erythropoietic Effects
Current Neurovascular Research Macrolides as Immunomodulatory Agents: Review and Future Directions
Medicinal Chemistry Reviews - Online (Discontinued) Fasting Insulin and Risk of Cancer Related Mortality in Non-diabetic Adults: A Dose-response Meta-analysis of Cohort Studies
Current Diabetes Reviews Inflammation and Antiangiogenesis in Cancer
Current Medicinal Chemistry Anti-Angiogenesis in the Treatment of Genito-Urinary Cancers: Last Updates
Current Angiogenesis (Discontinued) Antitumorigenic Effect of Memantine via Interfering Glutamate Metabolism in Mouse 4T1 Breast Tumor Model
Anti-Cancer Agents in Medicinal Chemistry Strategic Developments & Future Perspective on Gene Therapy for Breast Cancer: Role of mTOR and Brk/ PTK6 as Molecular Targets
Current Gene Therapy Rapid Characterization of a Novel Taspine Derivative-HMQ1611 Binding to EGFR by a Cell Membrane Chromatography Method
Combinatorial Chemistry & High Throughput Screening